Adstiladrin market report sees growth tied to bladder cancer demand and gene therapy adoption

The Business Research Company says the global market for Adstiladrin, a gene therapy for high-risk non-muscle-invasive bladder cancer, is being shaped by rising bladder cancer cases, higher healthcare spending, and broader adoption of precision oncology. North America led the market in 2025, while Europe is expected to grow fastest through 2035.

Why it matters: - Adstiladrin targets high-risk non-muscle-invasive bladder cancer in patients who do not respond to BCG therapy. - The therapy gives patients another option before more invasive procedures such as radical surgery. - The market outlook reflects broader demand for gene-based cancer treatments and localized immunotherapy.

What happened: - The Business Research Company published its In-Depth Adstiladrin Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says the Adstiladrin market is expanding as bladder cancer cases rise and gene therapy adoption increases. - The report also identifies North America as the largest regional market in 2025. - Europe is projected to be the fastest-growing regional market over the forecast period.

The details: - Adstiladrin uses nadofaragene firadenovec, a non-replicating adenoviral vector, to deliver the interferon alfa-2b gene directly into bladder cells. - The treatment prompts the bladder to produce interferon alfa-2b locally, which helps stimulate immune activity against tumor cells. - Historical market growth has been driven by the limits of traditional BCG therapy, better gene delivery methods, rising bladder cancer rates, successful clinical outcomes with interferon therapies, and supportive regulatory frameworks. - Future growth is expected to come from broader gene therapy pipelines, more precision medicine use in oncology, higher investment in viral vector production, better long-term efficacy results, and greater awareness of NMIBC treatment options. - Key trends cited in the report include expanded gene therapy use in cancer care, a stronger focus on bladder cancer immunotherapy, wider use of viral vector technology, more targeted localized cancer treatment, and rising demand for therapies for BCG-unresponsive disease. - The report says bladder cancer incidence is increasing because of smoking, aging populations, environmental exposures, chronic bladder illnesses and improved diagnostic techniques. - The American Cancer Society reported 83,190 urinary bladder cancer cases in the US in January 2024, up from 82,290 in 2023. - UK healthcare spending rose 5.6% between 2022 and 2023, compared with 0.9% growth the year before, according to the Office for National Statistics. - The UK’s healthcare expenditure reached about $317.63 billion, or £292 billion, in 2023. - The report includes analysis of Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa alongside North America and Europe. - The company says its 2026 market reports also include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics, key technologies and future trend analysis, plus updated graphics and tables. - The report offers a free sample and a full report online through the company’s website: More information and the full report. - The company also provided contact details for media and sales inquiries, including Saumya Sahay and Oliver Guirdham, plus phone numbers, email and social media links.

Between the lines: - The report frames Adstiladrin as part of a larger shift toward precision oncology and gene therapy rather than a standalone bladder cancer product. - North America’s lead suggests the market is still being driven by advanced care systems and faster uptake of new cancer technologies. - Europe’s faster projected growth suggests more room for adoption as healthcare systems expand capacity and invest in precision medicine.

What's next: - The market will likely track clinical adoption, regulatory support, and whether gene-therapy manufacturing capacity keeps pace with demand. - Reported growth in bladder cancer diagnoses and healthcare spending could continue to support demand for Adstiladrin through 2035. - Investors and drug developers will be watching the broader gene therapy pipeline for evidence of durable efficacy and commercial scale.